Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions

Reuters

昨天

Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions

Stevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603964177"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603964177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603964177?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603964177","market":"nz","top_or_hot":-1,"title":"Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STVN\">Stevanato Group S.p.A.</a> has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-01-16 18:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STVN\">Stevanato Group S.p.A.</a> has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESNT.UK","symbol_name":"ESSENTRA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL2xNlQ5:1","article_id":"2603964177","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603964177","pubTimestamp":1768557954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Stevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill cartridges, and LTS Device Technologies' Sorrel Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESNT.UK":"ESSENTRA","STVN":"Stevanato Group S.p.A.","BK4121":"生命科学工具和服务","BK5031":"商品化工","BK4539":"次新股"},"translate_title":"Stevanato Group与Datwyler和LTS Device Technologies合作扩展自我递送药物解决方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESNT.UK":0.9,"STVN":0.9},"content_text":"Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions\n    \n\nStevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler's NeoFlex™ plungers for larger volume containers, Stevanato Group's ready-to-use EZ-fill® cartridges, and LTS Device Technologies' Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}